Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients
Kanvas Biosciences has raised a $48 million Series A, bringing its total funding to $78 million to advance novel microbiome therapeutics that improve responses to cancer immunotherapy. The round, co-led by DCVC and Lions Capital with participation from the Gates Foundation, ATHOS, Germin8, Ki Tua Fund, Pangaea Ventures and others, will fund clinical trials for Kanvas’ lead drug candidates and expand its spatial imaging and manufacturing platform for next‑generation live biotherapeutics.